Reply  by Puggioni, Alessandra et al.
Regarding “Laser therapy and radiofrequency
ablation of the great saphenous vein: Analysis of early
efficacy and complications”
Puggioni et al1 describe 77 patients undergoing the EVLT
procedure with an occlusion rate of 94% and ultrasound findings of
clot propagation in three limbs. Comparable analysis in the group
treated with radiofrequency was not done in regards to early duplex
evaluation postprocedure. This experience with saphenous vein abla-
tion, although small, is considerably different from ours in that they
report a 4% incidence of clot propagation into the femoral vein.
We have treated 1800 patients since January 2001 using the
940-diode laser (Skin Pulse S, Dornier MedTech America, Inc,
Kennesaw, Ga). About 90% of those vessels treated were the great
saphenous vein. Other veins treated included the short saphenous,
anterolateral branch, and the thigh extension branch.
All vessels were scanned immediately postprocedure and 2 to 5
days later. One patient, a 55-year-old woman, had an extension of
the saphenous clot into the femoral vein. She was treated with
aspirin and low-molecular-weight heparin for 5 days until resolu-
tion of the thrombus was documented by ultrasound scanning.
The other patient was a 23-year-old woman with a clot extension
into the popliteal vein after short saphenous vein ablation. In this
case, low-molecular-weight heparin was used initially with Couma-
din (Dupont Pharma, Wilmington, Del) for 3 months thereafter.
Our technique intraoperatively is similar to that described,
with minor variations. Application of laser energy begins 1.5- to
2-cm distal to the inferior epigastric vein. Our histologic studies, at
least with the 940 wavelength, have shown there is little if any
thermal damage beyond 1 cm if a pullback is progressing.2 This was
confirmed by microscope evaluation (intact adventitial vessels) of
veins treated with varying energies and pulse durations. An energy
application of 1 second does not affect the vein wall, only the
endothelium and subendothelium. This may be in part due to the
higher hemoglobin affinity for the 940 wavelength.
Steam bubble formation has been described previously and is
thought to be the causation of thermal injury to the vein.3 If very few
steam bubbles are seen proximal to the inferior epigastric vein, then
thermal injury is unlikely to occur; hence, normal flow will persist in
this segment. Rarely do steambubbles occur 2 to 3 cm from the point
of energy application. Owing to higher hemoglobin absorption with
the 940 wavelength, remote thermal injury is more unlikely.
We use no conscious sedation or regional anesthetic. All of our
procedures are done with ultrasound-directed dilute Xylocaine
(AstraZeneca Pharma, Wilmington, Del) injection.4 Mild com-
pression is applied over the saphenofemoral junction during the
initial 5 to 8 cm of treatment, ensuring that no damage occurs from
thermal transmission by steam bubbles. This is done by using the
ultrasound probe to compress the saphenofemoral junction. Oc-
clusion of the saphenous vein at the junction with an uncom-
pressed femoral vein is easily visualized. Postprocedure, our pa-
tients are wrapped with a three-layer compression dressing. After 2
days, 20-mm compression hose are worn. All patients receive
ibuprofen (800 mg, thrice daily) for 1 week. This is done not only
for analgesia but also for the mild antiplatelet effect at this dose.
Second, the group reports an effective occlusion rate of 94.4%.
I would like to ask the authors if the amount of energy delivered is
sufficient. In our experience, the total energy delivered is usually in
the range of 100 to 125 J/cm. From their description, there is
much less energy delivered.
Ronald G. Bush, MD
Midwest Vein Treatment Clinic
Dayton, Ohio
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Reply
We appreciate the points raised by Dr Bush regarding the
incidence of extension of great saphenous vein thrombus into the
femoral vein after endovenous laser therapy (EVLT) ablation in
our series. We have discussed this issue in a previous communica-
tion in greater detail.1 We again emphasize the importance of
routine postoperative imaging within 24 to 48 hours to identify
and appropriately treat thrombus extension.
Based on our experience, we believe that the etiology of this
phenomenon is multifactorial (ie, hypercoagulable state, patient age,
prolonged immobilization, too much blood in the great saphenous
vein) but agree that technique undoubtedly plays an important role.
We perform EVLT using the technique published by Min et al,2
which involves advancing thewire, sheath, and probe into the femoral
vein followed by withdrawal into the great saphenous vein for final
positioning. No deep venous thrombosis was reported in their series
of 499 patients despite commencing the ablation above the inferior
epigastric vein (5 to 10 mm from the saphenofemoral junction) as
opposed to 1.5 to 2 cm below the epigastric vein as recommended by
Dr Bush. We position the laser probe 10 mm distal to the epigastric
vein and keep manipulation above this level to a minimum to mini-
mize thrombus extension.
We agree that steam bubbles rarely propagate 2 to 3 cm from
the point of energy application, as we have also observed bubble
generation under ultrasound imaging during the course of the
procedure. It is unlikely that there was venous wall injury in the
femoral vein from steam bubbles in any of these cases, as all
thrombus extensions were nonocclusive with attachment to the
saphenous vein thrombus rather than the wall of the femoral vein.
We have not employed compression of the saphenofemoral junc-
tion, but do initiate withdrawal of the probe immediately upon
commencing the ablation to prevent full thickness injury of the
vein wall.
Regarding the amount of laser energy delivered, we have
followed the recommendations of the 810-mm diode laser manu-
facturer (Diomed, Andover, Mass) as well as the technique de-
scribed by Min et al,2 with satisfactory rates of occlusion (94.4%).
This involves delivering laser energy at 14W in a continuous mode,
with withdrawal of the catheter at 3 mm/s, making the energy
delivered approximately 50 J/cm.
Previous studies3,4 have confirmed that EVLT failure seems to
be related to the administration of lower laser fluence; however,
there are no published studies looking at the effect of energies
100 J/cm on treatment success. The need for higher energy
delivery noted by Dr Bush et al may be related to the higher
hemoglobin absorption with the 940-mm wavelength laser. We
have learned with experience that complete emptying of the vein
with elevation and adequate tumescent anesthesia ensures direct
injury to the vein wall and avoids thrombotic occlusion of the
saphenous vein, both to decrease the chance of thrombus exten-
sion as well as recanalization in the long-term. In addition, we use
now a single dose of low-molecular-weight heparin perioperatively
to further decrease the risk of thrombotic complications in selected
high-risk patients.
Thrombus extension into the femoral vein caused no symp-
toms in our patients, and this complication appears much more
benign than a femoropopliteal or iliac deep vein thrombosis
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(DVT). It needs a much shorter course of anticoagulation. Still,
pulmonary embolism can occur and lack of treatment may cause
extension of the thrombosed vein segment. Thrombus extension
from the saphenous vein into the femoral vein can occur not only
in spontaneous saphenous thrombophlebitis but also after laser or
radiofrequency ablation, and after foam sclerotherapy or open high
ligation of the saphenous vein. Its incidence was 10% (3 of 30) in
the small saphenous vein after 30 endovenous laser therapy, as
reported recently by Gibson et al.5 Gradman et al6 documented
pulmonary embolism after EVLT. In 7611 EVLT procedures,
Kabnick7 observed DVT in 0.27% and pulmonary embolism in
0.023%. When foam sclerotherapy was used for saphenous abla-
tion, the incidence of DVT was 2.9% (16 of 558) in the series
reported by Wright and Rush.8 Hingorani et al9 reported an incidence
of DVT of 16% after radiofrequency ablation, and Merchant et al10
reported an incidence of about 1%.
We must remain vigilant and should do everything to prevent,
diagnose, and treat early thrombotic complications of endovenous
procedures.
Alessandra Puggioni, MD
Manju Kalra, MBBS
Peter Gloviczki, MD
Division of Vascular Surgery
Mayo Clinic
Rochester, Minn
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Regarding “3-Hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors reduce the risk of perioperative
stroke and mortality after carotid endarterectomy”
We read with great interest the recent article by McGirt et al
(J Vasc Surg 2005;42:829-36). Recently, several trials reported
beneficial effects of statins on perioperative cardiovascular out-
come in patients undergoing noncardiac vascular surgery. This
effect was ascribed to the pleiotropic ability of statins to “stabilize”
vulnerable (coronary) plaques.1,2 The study of McGirt et al is a
logical next step in clarifying the beneficial effects of statins in
vascular surgical patients.
The investigators report the outcome of 1566 consecutive pa-
tients who underwent carotid endarterectomy (CEA) at a single
academic center. A total of 657 patients who received statin therapy
for at least 1 week before surgery were compared with 909 patients
not on statin therapy. They concluded that statin use is associatedwith
a threefold-reduced risk of stroke and a fivefold-reduced risk of
perioperative death.We agree that statins may improve outcome after
CEA, but their report raises several questions.
First, the study sample ofMcGirt et al is rather heterogeneous.
Although the logistic regression model included a variable “symp-
tomatic carotid stenosis,” it is questionable whether symptomatic
and asymptomatic patients may be included in one model. Re-
cently, Kennedy et al3 published a comparable study that included
3238 patients undergoing CEA. That study clearly showed a more
pronounced beneficial effect of statins in symptomatic patients.
Because statins are thought to stabilize vulnerable plaques, it seems
logical to consider symptomatic (a proven vulnerable lesion) and
asymptomatic (no proof of a vulnerable lesion) as two entities. This
might especially apply to retrospective studies where not all radio-
graphic data on plaque composition are available.
Second, it would be of interest to know the cause of death of
patients in both groups. The authors describe a nonsignificant
difference in myocardial infarction (MI) between users and non-
users (1.2% vs 2.1%). It might well be that a combined end point of
MI and cardiac death would have reached statistical significance.
A major point of concern in this paper is the inaccuracy of
reporting the number of patients and events and inconsequent
statistical analysis. For example, in the text the authors report 25
MIs, whereas Table II states that 27 patients had a MI. In case of
such a small number of events, that is, eight MIs in statin users and
19 in nonusers, these two cases might have a profound impact on
the P value. What if the number of MIs would be 6 (0.9%) vs 19
(2.1%)? Another flaw in the statistical analysis is the omission of
“contralateral carotid stenosis” in the multivariate analysis of peri-
operative death. In the “Methods” section, it is clearly stated that
the authors planned to include all covariables with P  .10 in the
multivariate analysis. Why didn’t the authors do so and would this
have an impact on the significance (P  .044) of the beneficial
effect of statin use?
Niels F. M. Kok, MD
Department of Surgery
Erasmus MC
Rotterdam, The Netherlands
Linetta B. Koppert, MD
Department of Surgery
Reinier de Graaf Gasthuis
Delft, The Netherlands
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